Janux Therapeutics, Inc. (JANX)
JANX moved a median of +0.16% 30 minutes after news, and +0.12% by the close. How JANX actually reacts to news — the realized, point-in-time move the market made, measured across 327 labeled events over the last three years with zero look-ahead.
JANX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.15% | 56% | 327 |
| 30-min | +0.16% | 53% | 327 |
| 60-min | -0.07% | 49% | 327 |
| to close | +0.12% | 53% | 326 |
| Middle 50% of JANX reactions | -0.97% to +1.49% |
|---|---|
| Median reaction (30-min) | +0.16% |
| Measured reactions | 327 |
Half of all Janux Therapeutics, Inc. news events land between -0.97% and +1.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How JANX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.16% | 55% | +1.79% |
| Analyst downgrades | 10 | +0.51% | 70% | +2.00% |
| Coverage initiations | 45 | -0.74% | 36% | -0.41% |
| Rating reiterations | 63 | -0.13% | 46% | -0.08% |
| Price-target raises | 10 | +1.74% | 70% | -0.90% |
| Price-target cuts | 10 | +0.09% | 50% | -0.31% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how JANX ranks against every other measured name →
That’s how JANX usually reacts — get an email when it moves on news →Email me when JANX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JANX's baseline. Nothing else.
Recent JANX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 | Press release | Business Wire | +0.76% | +1.05% | |
| Form 10-Q Janux Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.89% | +0.76% | |
| Form 8-K Janux Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +0.76% | |
| Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | Business Wire | +0.89% | +0.76% | |
| Form 8-K Janux Therapeutics, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | -1.01% | |
| Form 8-K Janux Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | +0.36% | |
| Form 10-Q Janux Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.05% | -1.83% | |
| Form 8-K Janux Therapeutics, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -3.05% | -1.83% | |
| Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Press release | Business Wire | -3.05% | -1.83% | |
| Form 8-K Janux Therapeutics, Inc. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | -1.67% | |
| Form ARS Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.35% | -1.67% | |
| Form DEF 14A Janux Therapeutics, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +0.35% | -1.67% | |
| Form DEFA14A Janux Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.35% | -1.67% | |
| Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development | Press release | Business Wire | +1.12% | -4.10% | |
| Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 | Press release | Business Wire | +1.24% | +3.20% | |
| Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment | Press release | Business Wire | +1.50% | +2.83% | |
| Form 10-K Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.07% | +0.22% | |
| Form 8-K Janux Therapeutics, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +0.22% | |
| Form S-8 Janux Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.07% | +0.22% | |
| Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Press release | Business Wire | +1.07% | +0.22% | |
| Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 | Press release | Business Wire | +1.52% | +0.61% | |
| Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer | Press release | Business Wire | +1.68% | +2.16% | |
| Form 8-K Janux Therapeutics, Inc. For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | -1.00% | |
| Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors | Press release | Business Wire | -1.12% | +9.63% | |
| Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study | Press release | Business Wire | +1.46% | +1.56% | |
| Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC | Press release | Business Wire | -7.32% | -13.43% | |
| Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC | Press release | Business Wire | +2.83% | +8.80% | |
| Form 10-Q Janux Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.65% | -9.13% | |
| Form 8-K Janux Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | -9.13% | |
| Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | Business Wire | -0.65% | -9.13% | |
| Form 8-K Janux Therapeutics, Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | +1.16% | |
| Form 10-Q Janux Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.89% | +2.61% | |
| Form 8-K Janux Therapeutics, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.89% | +2.61% | |
| Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | Business Wire | +1.89% | +2.61% | |
| Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck | Press release | Business Wire | -2.75% | -4.43% | |
| Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day | Press release | Business Wire | -2.43% | +0.15% | |
| Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 | Press release | Business Wire | +0.47% | -5.51% | |
| Form 8-K Janux Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -2.62% | -6.38% | |
| Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer | Press release | Business Wire | +0.84% | +2.60% | |
| Form 10-Q Janux Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.63% | -3.37% | |
| Form 8-K Janux Therapeutics, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +3.63% | -3.37% | |
| Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | Press release | Business Wire | +3.63% | -3.37% | |
| Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates | Press release | Business Wire | +0.52% | -0.70% | |
| Form ARS Janux Therapeutics, Inc. For: Apr 25 | SEC filing · Form ARS | SEC EDGAR | -0.29% | +2.61% | |
| Form DEF 14A Janux Therapeutics, Inc. For: Apr 25 | SEC filing · Form DEF | SEC EDGAR | -0.29% | +2.61% | |
| Form DEFA14A Janux Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.29% | +2.61% | |
| Form 10-K Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.22% | +1.61% | |
| Form 8-K Janux Therapeutics, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +1.61% | |
| Form S-8 Janux Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.22% | +1.61% | |
| Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights | Press release | Business Wire | +0.22% | +1.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JANX section they belong to.
Where else JANX is measured.
JANX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Janux Therapeutics, Inc.'s median reaction calculated?
Every labeled JANX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 327 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of JANX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JANX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.